Grants and Contributions:
Title:
Newcastle Disease Virus (NDV) as a novel platform for development of COVID-19 vaccines
Agreement Number:
964417
Agreement Value:
$303,341.00
Agreement Date:
Jan 21, 2021 - Jan 17, 2022
Description:
The University of Guelph developed a vaccine to protect against the novel coronavirus disease that emerged in 2019 (COVID-19) using a safe vector known as avian orthoavulavirus-1 (AOaV-1) with a transgene encoding the full-length spike protein (FLS) from severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). In a hamster challenge model of COVID-19, intranasal vaccination with AOaV-1-FLS completely protected against disease, and SARS-CoV-2 could not be detected. This correlated with the induction of a SARS-CoV-2-specific immune responses in the lungs. The next step requires that this vaccine be optimized for administration into the respiratory system of humans. Specifically, the vaccine vector needs to be adapted to function across a broad range of temperatures, including the relatively low temperature of the nasal passages and the higher temperatures in the lungs. Also, intranasal versus aerosol delivery into the respiratory system will be tested to determine if nasal and/or respiratory delivery induces protective immune responses. In parallel, a next-generation version of the vaccine that expresses a prefusion stabilized SARS-CoV-2 spike protein will be engineered and tested in mice and hamster COVID-19 challenge models. This research will pave the way toward a human clinical trial.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Guelph, Ontario, CA N1G 2W1
Reference Number:
172-2020-2021-Q4-964417
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
108161829
Recipient Type:
Academia
Recipient's Legal Name:
University of Guelph
Federal Riding Name:
Guelph
Federal Riding Number:
35032
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710 - R&D in the physical, engineering and life sciences